Clinical study

SGDC-VAP

The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia

Status	Completed
Type	Trial
Countries	Russia
Conditions studied	Trauma Injury; Brain Injuries; Abdominal Sepsis; Pancreatitis; Meningitis; Encephalitis; Seizures; Acute Respiratory Distress Syndrome
Study years	2020–2023
Entry review	2026-10-03

Participation

Check the study record or contact the study team for current recruitment and eligibility.

Study eligibility

Inclusion Criteria: \- invasive mechanical ventilation beyond 48 hours Exclusion Criteria: * hospital - acquired pneumonia * community - acquired pneumoniae * BMI \> 35 kg/cm2 * pregnancy * tracheostomy * reintubation

Study description

Oropharynx is the main source of pathogen microorganisms for the ventilator - associated pneumoniae. As known bacteriophages can eliminate different pathogen microorganisms or reduce a degree of a pathogen's colonization. The research team is considering that oropharyngeal decontamination with bacteriophages can prevent the developing of the ventilator - associated pneumoniae. There will be three groups in this investigation: placebo, antiseptic drug (Octenisept) and bacteriophage (Sexthaphag).

Study registrations

ClinicalTrials.gov	NCT04325685

Recorded study locations (1)

Locations listed in the study record; this does not confirm current recruitment or treatment outside the study. A site label may be older than the overall study status.

Budgetary Healthcare Institution of Arkhangelsk Region "Severodvinsk City Clinical Emergency Hospital # 2"

Severodvinsk, Arkhangelskaya oblast, Russia

Recorded site status: Not separately listed. Study location source ↗

Sources and updates

Entry reviewed 2026-10-03. This is the date of our source review, not a confirmation of availability today.

NCT04325685

AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.

Study ID	nct04325685